Skin Cancers

• ESMO Summit Latin America 2019
• Clinical Case Presentations
• Immuno Oncology Melanoma
• Current Standards Care Melanoma
• Practice Changing Studies Melanoma
• Proffered Paper session 1
• Participant Clinical Case Discussion: Metastatic Melanoma with Pneumonitis
• Melanoma Advanced and Adjuvant
• Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients
• 30 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopi...
• Update on adjuvant therapy in advanced melanoma
• Early development programs in advanced melanoma
• Adoptive cell therapy in melanoma
• Successful use of interferon-alpha and adoptive T cell therapy for metastatic melanoma patients failing other treatment options
• Proffered Paper session II - Invited Discussant 31O, 32O and 68O
• ESMO Immuno-Oncology Congress 2018
• Merkel cell carcinoma
• Uveal melanoma
• Immunotherapy vs. targeted therapy in first-line treatment of mutation positive metastatic melanomas: How does one choose?
• Discussion led by moderators
• The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors
• PD-L1 expression and clinical outcome after nivolumab monotherapy in various subtypes of melanoma: a single-institutional retrospective study
• A pilot study of intrahepatic Yttrium-90 microsphere radioembolisation in combination with intravenous cisplatin for uveal melanoma liver-only meta...
• Local disease control of nasal malignant melanoma achieved by administration of nivolumab followed by palliative radiation: a case report
• Complete response of BRAF-mutated metastatic melanoma treated with dabrafenib and trametinib in a super-elderly patient: a case report

• « Previous
• 1
• 2
• ...
• 25
• Next »